Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0781
    -0.0013 (-0.12%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2621
    -0.0001 (-0.01%)
     
  • USD/JPY

    151.3710
    -0.0010 (-0.00%)
     
  • Bitcoin USD

    70,344.96
    +68.11 (+0.10%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

CLASS ACTION UPDATE for BSX, TCDA and DECN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / January 20, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

BSX Shareholders Click Here: https://www.zlk.com/pslra-1/boston-scientific-corporation-loss-submission-form?prid=12289&wire=1
TCDA Shareholders Click Here: https://www.zlk.com/pslra-1/tricida-inc-loss-submission-form?prid=12289&wire=1
DECN Shareholders Click Here: https://www.zlk.com/pslra-1/decision-diagnostics-corp-loss-submission-form?prid=12289&wire=1

* ADDITIONAL INFORMATION BELOW *

Boston Scientific Corporation (NYSE:BSX)

BSX Lawsuit on behalf of: investors who purchased April 24, 2019 - November 16, 2020
Lead Plaintiff Deadline : February 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/boston-scientific-corporation-loss-submission-form?prid=12289&wire=1

According to the filed complaint, during the class period, Boston Scientific Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional and threatened the continued viability of the entire product line; (ii) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Tricida, Inc. (NASDAQ:TCDA)

TCDA Lawsuit on behalf of: investors who purchased September 4, 2019 - October 28, 2020
Lead Plaintiff Deadline : March 8, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tricida-inc-loss-submission-form?prid=12289&wire=1

According to the filed complaint, during the class period, Tricida, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Tricida's NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Decision Diagnostics Corp. (OTCMKT:DECN)

DECN Lawsuit on behalf of: investors who purchased March 3, 2020 - December 17, 2020
Lead Plaintiff Deadline : March 16, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/decision-diagnostics-corp-loss-submission-form?prid=12289&wire=1

According to the filed complaint, during the class period, Decision Diagnostics Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) Decision Diagnostics had not developed any viable COVID-19 test, much less a test that could detect COVID-19 in less than one minute; (ii) the Company could not meet the FDA's EUA testing requirements for its purported COVID-19 test; (iii) accordingly, Defendants had misrepresented the timeline within which it could realistically bring its COVID-19 test to market; (iv) all the foregoing subjected Defendants to an increased risk of regulatory oversight and enforcement; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/625084/CLASS-ACTION-UPDATE-for-BSX-TCDA-and-DECN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Advertisement